drugset / Trial / NCT00368537

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

NCT00368537

Phase 4 Completed 550 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).

Timeline

Start
2006-09
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1.2 g Intravenous
Comparator Ampicillin Unknown 1.5 g Intravenous
Comparator Ampicillin Unknown 3 g Intravenous
Comparator Tigecycline Small molecule 50 mg Intravenous